BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-354@pharmaconomics
DTSTAMP:20260707T034714Z
DTSTART;VALUE=DATE:20260327
DTEND;VALUE=DATE:20260328
SUMMARY:REPL PDUFA — RP1 (vusolimogene oderparepvec)
DESCRIPTION:The FDA's approval decision on RP1 (vusolimogene oderparepvec) for advanced melanoma is due Mar 27\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1737953/000110465926078009/tm2619037d1_8k.htm\n\nTrack it: https://www.pharmaconomics.com/e/354
URL:https://www.pharmaconomics.com/e/354
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:REPL catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR